Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imzokitug + Pumitamig + PDCT vs Pumitamig + PDCT in First-line Advanced/Metastatic NSCLC
NCT07680764Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 12
01
Overview
A Phase 2 trial of imzokitug in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Sep 2026; status: recruiting.
02
Drugs
imzokitug
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07680764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07680764.